Fisher Asset Management LLC cut its position in Stryker Corporation (NYSE:SYK – Free Report) by 4.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 378,378 shares of the medical technology company’s stock after selling 17,396 shares during the period. Fisher Asset Management LLC owned about 0.10% of Stryker worth $104,202,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Eurizon Capital SGR S.p.A. raised its position in Stryker by 16.3% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 107,386 shares of the medical technology company’s stock valued at $29,587,000 after buying an additional 15,048 shares during the last quarter. Nikulski Financial Inc. boosted its holdings in shares of Stryker by 6.1% in the 3rd quarter. Nikulski Financial Inc. now owns 8,762 shares of the medical technology company’s stock valued at $2,413,000 after buying an additional 502 shares during the last quarter. R Squared Ltd acquired a new stake in shares of Stryker in the 3rd quarter valued at approximately $351,000. Maryland State Retirement & Pension System grew its stake in shares of Stryker by 15.3% in the third quarter. Maryland State Retirement & Pension System now owns 21,396 shares of the medical technology company’s stock valued at $5,892,000 after buying an additional 2,835 shares in the last quarter. Finally, NBH Bank raised its position in Stryker by 2.8% during the third quarter. NBH Bank now owns 1,516 shares of the medical technology company’s stock worth $417,000 after acquiring an additional 42 shares in the last quarter. 77.09% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on SYK. UBS Group decreased their price objective on shares of Stryker from $400.00 to $382.00 and set a “buy” rating for the company in a research report on Monday, August 3rd. Raymond James Financial reaffirmed an “outperform” rating and issued a $323.00 target price (down from $370.00) on shares of Stryker in a report on Friday, October 30th. Truist Financial reiterated a “hold” rating and issued a $305.00 target price (down from $310.00) on shares of Stryker in a research note on Monday, November 2nd. Wells Fargo & Company reduced their price target on Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a report on Wednesday, September 9th. Finally, Robert W. Baird reduced their price target on Stryker from $385.00 to $334.00 in a report on Friday, October 30th. Twenty-one investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $342.19.
View Our Latest Stock Analysis on Stryker
Stryker Trading Down 0.2%
Shares of Stryker stock opened at $309.05 on Monday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30. The business has a fifty day simple moving average of $292.30 and a two-hundred day simple moving average of $322.60. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $389.33. The company has a market capitalization of $117.65 billion, a price-to-earnings ratio of 32.91, a P/E/G ratio of 2.13 and a beta of 0.78.
Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03). The company had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.74%. Stryker’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.19 earnings per share. Research analysts forecast that Stryker Corporation will post 14.85 EPS for the current year.
Insider Buying and Selling
In related news, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 901,267 shares of company stock valued at $297,123,701. Company insiders own 4.60% of the company’s stock.
About Stryker
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Recommended Stories
- Five stocks we like better than Stryker
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
